Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Genomics ; 113(6): 3610-3617, 2021 11.
Article in English | MEDLINE | ID: mdl-34352367

ABSTRACT

Excessive prenatal opioid exposure may lead to the development of Neonatal Opioid Withdrawal Syndrome (NOWS). RNA-seq was done on 64 formalin-fixed paraffin-embedded placental tissue samples from 32 mothers with opioid use disorder, with newborns with NOWS that required treatment, and 32 prenatally unexposed controls. We identified 93 differentially expressed genes in the placentas of infants with NOWS compared to unexposed controls. There were 4 up- and 89 downregulated genes. Among these, 7 genes CYP1A1, APOB, RPH3A, NRXN1, LINC01206, AL157396.1, UNC80 achieved an FDR p-value of <0.01. The remaining 87 genes were significant with FDR p-value <0.05. The 4 upregulated, CYP1A1, FP671120.3, RAD1, RN7SL856P, and the 10 most significantly downregulated genes were RNA5SP364, GRIN2A, UNC5D, DMBT1P1, MIR3976HG, LINC02199, LINC02822, PANTR1, AC012178.1, CTNNA2. Ingenuity Pathway Analysis identified the 7 most likely to play an important role in the etiology of NOWS. Our study expands insights into the genetic mechanisms of NOWS development.


Subject(s)
Neonatal Abstinence Syndrome , Opioid-Related Disorders , Analgesics, Opioid/therapeutic use , Carrier Proteins , Female , Gene Expression Profiling , Humans , Infant , Infant, Newborn , Membrane Proteins , Neonatal Abstinence Syndrome/complications , Neonatal Abstinence Syndrome/drug therapy , Neonatal Abstinence Syndrome/genetics , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/genetics , Placenta , Pregnancy
SELECTION OF CITATIONS
SEARCH DETAIL